High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria

Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient’s perspective as well as treatment outcomes at 3 high-volume faci...

Descripción completa

Detalles Bibliográficos
Autores principales: Abudiore, Opeyemi, Amamilo, Ikechukwu, Campbell, Jennifer, Eigege, Williams, Harwell, Joseph, Conroy, James, Jiboye, Justus, Lufadeju, Folu, Amole, Carolyn, Wiwa, Owens, Anweh, Damien, Agbaji, Oche Ochai, Akanmu, Alani Sulaimon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191360/
https://www.ncbi.nlm.nih.gov/pubmed/37196012
http://dx.doi.org/10.1371/journal.pone.0284767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191360/
https://www.ncbi.nlm.nih.gov/pubmed/37196012
http://dx.doi.org/10.1371/journal.pone.0284767

Ejemplares similares